Future of Drug Discovery - Murat Tunaboylu

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Site

RSS

Apple

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://www.antiverse.io/
12 partages
https://share.hsforms.com/1ybacT57PSl26j5ImyAEQVA8o2g0
6 partages
https://hubs.la/Q022vyTF0
5 partages

https://www.linkedin.com/company/antiverse/
16 partages
https://www.linkedin.com/in/murattunaboylu/
4 partages
https://www.linkedin.com/in/ashwinighogare/
2 partages

https://youtu.be/XKJFFcFMt5c?feature=shared
3 partages
https://youtu.be/5l69jvIu5DQ
3 partages
https://www.youtube.com/watch?v=F9kADawRPOs
2 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Rahmad Akbar - Frontiers of AI Antibody Design (FODD #17)

Saison 1 · Épisode 17

mardi 3 septembre 2024 • Durée 26:19

This episode is a discussion between ⁠Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu⁠, Co-Founder and CEO of Antiverse⁠.

You will learn:

The impact antibody design has on the world.
How AI is helping to push antibody design forward, bringing new therapies to patients.
What will antibody design look like in the future?

Rahmad's LinkedIn page.

Rahmad's Personal Website.

Antibody Origami: Here.

Rahmad's Previous and Existing Team: Victor Greiff (GreiffLab). Paolo Marcatili, Ludovica Beltrame, Rasmus Høiberg-Nielsen (Antibody Design at Novo Nordisk).

"And a big shout out to budding antibody designers (scientists) everywhere especially from my home country Indonesia!' - Rahmad.

Be sure to like, rate and review the podcast if you enjoyed this episode! Visit our website: https://www.antiverse.io/ Follow us: LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠⁠ X: ⁠⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

Lire plusRéduire

Paul Essery and Murat Tunaboylu - Founding an AI Drug Discovery Start-Up (FODD #16)

Saison 1 · Épisode 16

mardi 23 juillet 2024 • Durée 14:07

This episode is a discussion between Paul Essery, Host of 'The Tech Business Podcast' and Murat Tunaboylu Co-Founder and CEO of Antiverse.

You will learn:

The CEO journey and how Antiverse was founded.
How artificial intelligence is solving challenging targets in antibody discovery.
Successes and challenges of being a biotech founder (+advice for aspiring entrepreneurs).

Be sure to like, rate and/or review the podcast if you enjoyed it!

Visit our website: https://www.antiverse.io/

LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠

X: ⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

Lire plusRéduire

FODD 7 - Alan Nafiiev - Receptor AI - Membranotropic Drug Discovery

Saison 1 · Épisode 7

mardi 7 mars 2023 • Durée 31:33

In this episode, we speak with Alan Nafiiev, Co-Founder and CEO of ‘RECEPTOR.AI’, an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets.

Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and services are streamlining the drug discovery process for pharmaceutical and biotech companies. He also discusses how Receptor AIs technology can automate and customise drug discovery pipelines.

To conclude, Alan explains Receptor AIs plans for 2023 - branching into membranotropic drug discovery for cancer and cardiovascular diseases, through designing drugs against unique membrane environments.

Things mentioned:

Sergii Starosyla, Co-Founder and CTO of Receptor AI.
Semen Yesylevskyy, Co-Founder and CSO of Receptor AI.
Enamine, a partner to Receptor AI.

Additional Materials:

FODD 6 - Tom Fleming - Better Data Today. Better Drugs Tomorrow.

Saison 1 · Épisode 6

dimanche 16 octobre 2022 • Durée 31:41

Arctoris COO Tom Fleming talks about automation and building a small molecule discovery platform

FODD 5 - Tim Jenkins - AI Bites Back!

Saison 1 · Épisode 5

jeudi 31 mars 2022 • Durée 31:04

In this episode, our guest Assistant Prof. Tim Jenkins talks about snakebites and how to use AI to design broadly neutralising antibodies against venoms. Tim takes us through his experience at Milner Therapeutics Institute and shares his passion and vision for connecting academia and startups/industry players. In the second half of this talk, Tim explains the complexity in the venom domain and the challenges that lie ahead for the commercialisation of antivenom antibodies.

PS: Recently, with InstaDeep, Tim has posed a snake antivenom challenge as part of the largest hackathon in Africa.

Lire plusRéduire

FODD 4 - Andrew Martin - abYsis and Antibody Developability

Saison 1 · Épisode 4

dimanche 13 mars 2022 • Durée 41:50

In episode 4, Murat talks with Andrew C. R. Martin, Professor of Bioinformatics and Computational Biology at UCL, about abYsis (a fully integrated antibody discovery system) and the latest antibody developability tools!

Following the origin story of abYsis, you will hear the differences between the public and commercial versions such as data persistence and security, as well as new tools such as abYmod and abYdraw.

At the end of the talk, the discussion moves into developability (stability and Immunogenicity).

Antiverse - Engineering the future of drug discovery - https://www.antiverse.io/

To obtain an abYsis license contact Chemogenomix.

To be an abYdraw beta tester contact Andrew Martin.

Lire plusRéduire

FODD 3 - Konrad Krawczyk - Natural Antibody (Antibody Datasets and ML)

Saison 1 · Épisode 3

dimanche 6 mars 2022 • Durée 32:17

Future of Drug Discovery Episode #3

In this session, Murat talks with Konrad Krawczyk, Assistant Professor SDU and Founder of NaturalAntibody.

We will be covering Mr Natural Antibody's views on developing and using bioinformatics tools to analyse and discover biologics.

Other topics in this episode:

- Changing role of bioinformatics from assisting to being the main driver in biologics discovery
- 99% of the job is to get quality data, 1% is computational methods
- Collecting data from Patents, Scientific Publications, NGS, Therapeutics from FDA
- Developing models for binding prediction and biophysical properties
- Predictions of binding and developability, database, tool access, and expertise
- Interpretability of ML models

Antiverse - Engineering the future of drug discovery - https://www.antiverse.io/

Lire plusRéduire

FODD 2 - Ryan Kelly - 100+ discovery campaigns against challenging targets

Saison 1 · Épisode 2

jeudi 17 février 2022 • Durée 32:10

In this episode, Murat talks with Ryan Kelly about Abveris (employee #3) and how to run 100+ discovery campaigns against challenging targets.

FODD 1 - Victor Greiff - Immunology and Machine Learning Applied to Drug Discovery

Saison 1 · Épisode 1

samedi 5 février 2022 • Durée 29:39

FODD 1 - Victor Greiff - Immunology and Machine Learning Applied to Drug Discovery

Björn Schimmöller - Inorganic Chemistry at the Frontier of Immunotherapy (FODD #15)

Saison 1 · Épisode 15

mercredi 17 janvier 2024 • Durée 22:02

In this episode, we speak with ⁠⁠Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.

Host: ⁠⁠Murat Tunaboylu⁠⁠, Co-Founder and CEO of Antiverse.

You will learn:

The founding journey of iuvantium from Oxford University.
How Iuvantium is enhancing immune system efficiency and reducing clinical trial uncertainty using inorganic chemistry.
‘Decoding’ the immune system and how personalised medicine may lead to the next leaps in immunotherapy.

Things mentioned:

⁠⁠AstraZeneca COVID-19 vaccine
John Austyn - CSO and Co-Founder of Iuvantium
Ralph Steinman
Farooq Khan - AI Architect at Iuvantium
‘Artificial Lymph Nodes’
Simon Sinek - The Infinite Game

Podcasts et contenus similaires

Autres podcasts ou contenus associés partageant des thèmes ou audiences similaires.

Future of Drug Discovery – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts Similaires Basées sur le Contenu

Apple Podcasts

Spotify

Podcasts Similaires Basées sur le Contenu

Future of Drug Discovery – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Other71

LinkedIn28

Youtube8

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Apple Podcasts

Spotify

Podcasts Similaires Basées sur le Contenu

Other71

LinkedIn28

Youtube8